Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$28.83 USD
+0.06 (0.21%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $28.83 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DNTH 28.83 +0.06(0.21%)
Will DNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Other News for DNTH
J&J submits FDA application for myasthenia gravis drug nipocalimab
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Promising Clinical Developments Bolster Buy Rating for Dianthus Therapeutics
Navigating 4 Analyst Ratings For Dianthus Therapeutics
Commit To Buy Dianthus Therapeutics At $25, Earn 26.1% Annualized Using Options